Dr. Arianna Gentilini

a.gentilini@imperial.ac.uk | +44 7706 549 539 | London, United Kingdom

Academic Employment

British Academy Postdoctoral Fellow, Dept. of Economics & Public Policy, Imperial College London, London Nov 2026 – 2030

– **Investigator** of a three-year research programme on drug repurposing, (£ 580,176)

Postdoctoral Research Associate, Dept. of Economics & Public Policy, Imperial College London, London 2024 – 2026

– **Co-investigator** of a £154k Gatsby Foundation project on pharmaceutical R&D productivity; responsible for methodology development, managing outputs, and partner coordination.
– Collaborator on **EU-funded Hi-Prix** project examining policies aimed at pharmaceutical **innovation** and **equitable access** to medicines globally; contributed comparative policy analyses and dissemination.

Senior Researcher, Medical Technology Research Group, London School of Economics & Political Science, London 2020 – 2024

– For **EU-funded IMPACT HTA**, applied **survival analysis** and multinomial models across multiple OECD countries to identify drivers of **reimbursement timelines/outcomes**, informing **HTA process** debates.
– Built a **compound–indication** database integrating HTA recommendations and funding decisions; enabled cross-country **comparative policy** insights.
– For the European Society of Medical Oncology, examined **misalignment** between oncology reimbursement decisions and clinical ratings to guide **value-based access**.

Qualifications

2020–2024 **Ph.D. (ESRC-funded), Health Policy and Economics**, London School of Economics and Political Science (London).
Thesis: "The role of patient organisations in innovation and access to medicine: Evidence from rare diseases".
Supervisors: Prof. Panos Kanavos; Prof. Alistair McGuire; Prof. Andrew Street.

2017–2018 **M.Sc., International Health Policy and Health Economics** (*with distinction*), London School of Economics and Political Science (London).
Thesis: "Physical activity, diet or both to improve type 2 diabetes mellitus risk factors in diabetic and prediabetic adults: a network meta-analysis and microsimulation analysis".

2013–2016 **B.Sc., International Economics** (*with honours*), Università degli Studi di Padova.
Exchanges: Université de Versailles Saint-Quentin-en-Yvelines (Fall 2015), Erasmus; University of Michigan (Summer 2015), Summer Program in Management.

Non-academic employment

Health Economist, Health Economics & Decision Modelling, National Institute for Health and Care Excellence, London 2026 – 2026

– Critically appraise **health economic models** and conduct **literature reviews**
– Contribute to the **application of severity modifiers** across guidelines to inform to NICE's **whole-lifecycle approach**.

Short-term Consultant, World Bank Group (Health, Nutrition and Population GP), *Remote* 2023 – 2026

- **Co-designed methodology** for *Pharmaceutical Sector Country Profiles* with WHO; curated indicators on regulation, access, and market enablers to support **country dialogue** and operations.
- **Assessed** delivery of **NCD services via pharmacies** and barriers/enablers in **Gabon, Senegal, and Zambia**; synthesized options to strengthen **primary care** and **supply chains**.
- **Reviewed logistics systems** for health commodities in **Pakistan**; mapped bottlenecks and identified **efficiency gains** for last-mile availability.

Consultant, PermaAnalytics, London 2024

- For the UK **National Institute for Health and Care Research**, developed an **economic evaluation** to assess the return-on-investment for five NIHR-funded projects, incorporating healthcare savings, QALY gains, and productivity gains over a 10-year horizon, to inform funding allocation decisions.

Consultant, Dolon Limited, London 2021 – 2022

- Developed a **risk-adjusted NPV model** for EU Orphan Regulation policy analysis; co-authored stakeholder consultation report; led payer workshops and built **value communication tools** for P&R submissions in **orphan/rare** diseases.

Associate Health Economist, Symmetron Limited, London 2018 – 2020

- Developed/adapted **cost-effectiveness** and **budget impact** models for national submissions (UK, Italy, China); conducted literature reviews and expert interviews to **localize** HTA models.

Teaching & supervision

Seminar Leader

- 2024 — **LSE**: Pharmaceutical Economics and Policy - MSc (Prof. Panos Kanavos)
- 2021 — **LSE**: Introduction to Quantitative Analysis - MSc (Prof. Patrick Sturgis)
- 2021 — **LSE**: Intermediate Quantitative Analysis - MSc/PhD (Prof. Patrick Sturgis)
- 2023 & 2024 — **Imperial College London**: Health Economics - MSc (Prof. Marisa Miraldo)
- 2023 & 2024 — **Imperial College London**: Health Economics - MSc (Prof. Laure de Preux)
- 2023 — **Imperial College London**: Research Methods & Practice - BSc (Prof. Sam Asher)
- 2023 — **Imperial College London**: Quantitative Methods - PhD (Prof. Paola Criscuolo)
- 2022 — **Imperial College London**: Health Care Financing - MSc (Prof. Pedro Rosa Dias)

Class Teacher 2023–2024LSE Health — Market Access Academy (in collaboration with Boston Consulting Group)

Publications

Peer-reviewed articles

- **Gentilini A**, Parvanova I, Ghazi S et al. (2026). *Patient organizations involvement in healthcare: a rapid review and conceptual framework. Globalization and Health.* doi.org/10.1186/s12992-026-01205-z
- **Gentilini A**, Raymakers AJN, Rand LZ (2026). *Conflicts of Interest in FDA Advisory Committees: A Systematic Literature Review. Value in Health.* doi.org/10.1016/j.jval.2026.01.018
- **Gentilini A**, Kasonde L, Babar ZUD (2025). *Expanding access to NCD services via community retail pharmacies in LMICs: a systematic review of the literature. Journal of Pharmaceutical Policy and Practice.* doi:10.1080/20523211.2025.2462450.
- **Gentilini A**, Neez E, Wong-Rieger D (2025). *Rare Disease Policy in High-Income Countries: An Overview of Achievements, Challenges, and Solutions. Value in Health.* doi:10.1016/j.jval.2024.12.009.

– **Gentilini A**, Rana A (2024). *How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals. European Journal of Health Economics.* doi:10.1007/s10198-024-01748-1.
– **Gentilini A**, Parvanova I (2024). *Managing experts' conflicts of interest in the EU Joint Clinical Assessment. BMJ Open.* doi:10.1136/bmjopen-2024-091777.
– Jenei K, **Gentilini A**, Haslam A, Prasad V (2024). *A retrospective comparative analysis of the clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the US, Canada, England, and Scotland. The Lancet Oncology.* doi:10.1016/S1470-2045(24)00286-9.
– **Gentilini A**, Miraldo M (2023). *The Role of Patient Organisations in Research and Development: Evidence from Rare Diseases. Social Science & Medicine.* doi:10.1016/j.socscimed.2023.116332.
– Kanavos P, Visentin E, **Gentilini A** (2023). *Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries. Social Science & Medicine.* doi:10.1016/j.socscimed.2023.116045.
– **Gentilini A**, Parvanova I (2023). *Industry Funding of Patient Organisations in the United Kingdom: A Retrospective Study of Commercial Determinants, Funding Concentration and Disease Prevalence. BMJ Open.* doi:10.1136/bmjopen-2022-071138.
– Parvanova I, **Gentilini A**, Cushing J, Naci H (2023). *Safeguarding NICE from patient groups' conflicts of interest. BMJ.* doi:10.1136/bmj.p1243.
– Rinciog C, Diamanthopulos A, **Gentilini A**, Bondue B, Dahlqvist C, Froidure A, Wuyts WA, Soulard S (2019). *The Cost-Effectiveness of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium. PharmacoEconomics Open.* doi:10.1007/s41669-019-00191-w.

Under review / submitted

– Mermelstein S, **Gentilini A**, Stevens H, Miraldo M (2025). *Do Policy Incentives Align with Pharmaceutical Innovation Challenges? A Retrospective Analysis of 42 Countries (2000–2022).* Submitted to *Health Affairs.*

Media Coverage

– Shanti Das and Jon Ungoed-Thomas (23 July 2023). "Revealed: drug firms funding UK patient groups that lobby for NHS approval of medicines." *The Observer.*

Honors, Fellowships and Research Grants

Jan 2027–2030 **British Academy Postdoctoral Fellowship** Competitive national award to lead an independent three-year research programme on drug repurposing, to be held at Imperial College London, Department of Economics and Public Policy (£ 580,176).

2024–2026 Co-investigator for a 2-year research project titled **"Drug Development Productivity – The Performance of the UK Biopharmaceutical Industry,"** funded by the Gatsby Foundation (£ 154,317).

2024 Highly Commended for the **LSE Class Teacher Awards** 2023–24.

2023 **"Italy Made Me"** award for outstanding research by Italian early-career researchers in the UK (£ 1,000).

2020–2024 **Economic and Social Research Council (ESRC) Doctoral Training Partnership** (fees plus £ 19,668 per annum).

Skills

Software Python, Stata, R, Excel, PowerPoint, LaTeX, Zotero, Rayyan, NVivo, PollEV
Languages English (fluent); Italian (native); French (intermediate); Spanish (intermediate).